Literature DB >> 28374504

Polymorphisms in the promoter region of iNOS predispose to rheumatoid arthritis in south Indian Tamils.

V S Negi1, C M Mariaselvam1,2, D P Misra1, N Muralidharan1, C Fortier3, D Charron2,3, R Krishnamoorthy2, R Tamouza2,3.   

Abstract

Nitric oxide synthase (NOS) catalyses the production of nitric oxide (NO) from L-Arginine, which participates in diverse biological processes including inflammation and apoptosis. Macrophages, chondrocytes, osteoblasts and osteoclasts express inducible NOS (iNOS) at the site of synovial inflammation. NO produced at the inflamed joint may contribute to peri-articular bone loss, mediate apoptosis and regulate Th1/Th2 balance in rheumatoid arthritis (RA). Variations in the promoter region of NOS gene regulate the nitric oxide synthase expression and iNOS (NOS2) polymorphisms have been associated with susceptibility to autoimmune disorders. Hence, this study was conducted to identify the possible contributions of NOS2 -1659G/A, -1026C/A, -277A/G promoter polymorphisms towards development of RA in South Indian Tamils. A total of 242 (219 females, 23 males) patients with RA (mean age 41.2 ± 10.9 years, disease duration 8.5 ± 4.3 years) and 279 age- and sex-matched healthy individuals of South Indian Tamil ethnicity were genotyped for NOS2 -1659C/T, -1026G/T and -277A/G promoter polymorphisms by TaqMan chemistry. Nature of disease (erosive or nonerosive), the presence of extra-articular manifestations, seropositivity for rheumatoid factor and anticyclic citrullinated peptide, serum C-reactive protein (CRP) level and response to therapy were assessed for all patients. The three single nucleotide polymorphisms (SNPs) were in Hardy-Weinberg equilibrium. The frequency of GG genotype and G allele of NOS2-277 was higher in patients (pc = 5.7 × 10-9 , OR = 6.09, 95% CI = 3.09-12.8 and pc = 4 × 10-13 , OR = 2.37, 95% CI = 2.06-3.62, respectively) compared to controls. Similarly, the frequency of NOS2-1026 (rs2779249) GT genotype and the T allele was higher in patients with RA (pc = .01, OR = 1.61, 95% CI = 1.09-2.36, and pc = .04, OR = 1.40, 95% CI = 1.02-1.91, respectively). However, no significant difference in frequency of NOS2-1659C/T polymorphism was observed between patients and controls. None of the studied SNPs were associated with erosive disease, seropositivity or extra-articular manifestations. The -277A/G and -1026 G/T promoter polymorphisms in iNOS may confer susceptibility to RA in South Indian Tamils.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  CRP; NOS2 promoter polymorphism; Rheumatoid arthritis; South India; Susceptibility; iNOS

Mesh:

Substances:

Year:  2017        PMID: 28374504     DOI: 10.1111/iji.12315

Source DB:  PubMed          Journal:  Int J Immunogenet        ISSN: 1744-3121            Impact factor:   1.466


  4 in total

1.  Inducible Nitric Oxide Synthase iNOS-954-G>C and Ex16+14-C>T Gene Polymorphisms and Susceptibility to Vitiligo in the Saudi Population.

Authors:  Fahad Al-Harthi; Ghaleb Bin Huraib; Md Mustafa; Yasser Al-Qubaisy; Naif Al-Nomair; Nour Abdurrahman; Abdulrahman Al-Asmari
Journal:  Pharmgenomics Pers Med       Date:  2022-06-13

2.  Association of NOS2A gene polymorphisms with susceptibility to bovine tuberculosis in Chinese Holstein cattle.

Authors:  Jun Chai; Qinglu Wang; Bo Qin; Shengkui Wang; Youtao Wang; Muhammad Shahid; Kai Liu; Yifang Zhang; Weijie Qu
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

3.  Isoprenyl phenolic ethers from the termite nest-derived medicinal fungus Xylaria fimbriata.

Authors:  Mei-Chuan Chen; Guei-Jane Wang; Yueh-Hsiung Kuo; Yin-Ru Chiang; Ting-Yu Cho; Yu-Ming Ju; Tzong-Huei Lee
Journal:  J Food Drug Anal       Date:  2018-06-18       Impact factor: 6.157

4.  Association of Polymorphisms in the Promoter Region of NOS2A Gene with Primary Knee Osteoarthritis in the Greek Population.

Authors:  Andreas Leonidou; Panagiotis Lepetsos; Eustathios Kenanidis; George Macheras; Maria Tzetis; Michael Potoupnis; Eleftherios Tsiridis
Journal:  Cureus       Date:  2020-01-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.